PharmaCyte Biotech, Inc. (PMCB) financial statements (2021 and earlier)

Company profile

Business Address 23046 AVENIDA DE LA CARLOTA, SUITE 600
LAGUNA HILLS, CA 92653
State of Incorp. NV
Fiscal Year End April 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2020
TTM
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments011323
Cash and cash equivalents011323
Other undisclosed current assets000001
Total current assets:011424
Noncurrent Assets
Long-term investments and receivables222222
Long-term investments222222
Intangible assets, net (including goodwill)444444
Intangible assets, net (excluding goodwill)444444
Other noncurrent assets000000
Total noncurrent assets:555555
TOTAL ASSETS:566979
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities111101
Accounts payable 00000
Accrued liabilities 10000
Employee-related liabilities0     
Other undisclosed accounts payable and accrued liabilities0     
Other undisclosed current liabilities0   01
Total current liabilities:111112
Noncurrent Liabilities
Total liabilities:111112
Stockholders' equity
Stockholders' equity attributable to parent456878
Common stock000000
Additional paid in capital107105102979186
Accumulated other comprehensive income (loss)(0)(0)(0)000
Accumulated deficit(103)(100)(96)(89)(85)(79)
Total stockholders' equity:456878
TOTAL LIABILITIES AND EQUITY:566979

Income statement (P&L) ($ in millions)

1/31/2020
TTM
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
Other income 00 0
Gross profit: 00 0 
Operating expenses(4)(4)(7)(4)(6)(13)
Other undisclosed operating loss (0)(0) (0) 
Operating loss:(4)(4)(7)(4)(6)(13)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 00(0)03
Interest and debt expense   (0)(0)3
Other undisclosed income from continuing operations before equity method investments, income taxes0     
Net loss:(4)(4)(7)(4)(6)(7)
Other undisclosed net income (loss) attributable to parent   00(3)
Net loss available to common stockholders, diluted:(4)(4)(7)(4)(6)(10)

Comprehensive Income ($ in millions)

1/31/2020
TTM
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
Net loss:(4)(4)(7)(4)(6)(7)
Other comprehensive income (loss)(0)(0)(0)0(0)0
Comprehensive loss:(4)(4)(7)(4)(6)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   00(3)
Comprehensive loss, net of tax, attributable to parent:(4)(4)(7)(4)(6)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: